Treatments:Cancer
From Proteopedia
(Difference between revisions)
| Line 17: | Line 17: | ||
* [[Methotrexate]] | * [[Methotrexate]] | ||
* Raltitrexed | * Raltitrexed | ||
| - | =====[[Epidermal Growth Factor Receptor]] | + | =====[[Epidermal Growth Factor Receptor]] Inhibitors===== |
* [[Herceptin]] - Generic: [[Trastuzumab]] | * [[Herceptin]] - Generic: [[Trastuzumab]] | ||
* [[Iressa]] - Generic: [[Gefitinib]] | * [[Iressa]] - Generic: [[Gefitinib]] | ||
| Line 30: | Line 30: | ||
* Afinitor - Generic: Everolimus | * Afinitor - Generic: Everolimus | ||
* Torisel - Generic: Temsirolimus | * Torisel - Generic: Temsirolimus | ||
| - | =====Multiple Receptor [[Tyrosine kinase]] ([[VEGFR]], PDGFR, [[EGFR]], KIT, Abl) | + | =====Multiple Receptor [[Tyrosine kinase]] ([[VEGFR]], PDGFR, [[EGFR]], KIT, Abl) Inhibitors===== |
* [[Gleevec]] - Generic: [[Imatinib]] | * [[Gleevec]] - Generic: [[Imatinib]] | ||
* [[Nexavar]] - Generic: [[Sorafenib]] | * [[Nexavar]] - Generic: [[Sorafenib]] | ||
| Line 39: | Line 39: | ||
=====[[Vascular Endothelial Growth Factor]] Inhibitor===== | =====[[Vascular Endothelial Growth Factor]] Inhibitor===== | ||
* [[Avastin]] - Generic: [[Bevacizumab]] | * [[Avastin]] - Generic: [[Bevacizumab]] | ||
| + | =====Poly ADP ribose polymerase (PARP) inhibitors====== | ||
| + | * [[Olaparib]] - brand name [[Lynparza]] | ||
</td> | </td> | ||
</tr> | </tr> | ||
</table> | </table> | ||
__NOTOC__ | __NOTOC__ | ||
Revision as of 06:51, 22 October 2023
Anti-CD20 Monoclonal Antibody
Anti-melanoma Monoclonal Antibody
B-Raf Kinase Inhibitor
Chemotherapy
Dihydrofolate Reductase Inhibitor
Epidermal Growth Factor Receptor Inhibitors
Estrogen Receptor Modulator
mTOR inhibitor
Multiple Receptor Tyrosine kinase (VEGFR, PDGFR, EGFR, KIT, Abl) Inhibitors
Vascular Endothelial Growth Factor Inhibitor
Poly ADP ribose polymerase (PARP) inhibitors= |
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Alexander Berchansky, Karsten Theis
